Search in site
Our implants are miniature, wireless, battery-less and fully-featured.
This is the future of Neurostimulation, enabling wider therapy acceptance by both physicians and patients
BlueWind Medical strives for the highest quality product and most advanced engineering and manufacturing processes. By placing the patient needs first, we have created a versatile and effective platform that will transform Neurostimulation as we know it.
In the pilot clinical study, 71% of patients implanted with the BlueWind Medical RENOVA™ iStim system experienced 50% or greater reduction in one or more OAB symptoms or a return to normal voiding at 6 months follow-up (1). BlueWind Medical is currently conducting OASIS, a pivotal IDE clinical trial, and has completed enrollment of 151 patients. BlueWind intends to submit 6-month and 12-month safety and efficacy data to the FDA in 2022.
(1) Heesakkers 2017